129
Participants
Start Date
October 5, 2020
Primary Completion Date
August 19, 2022
Study Completion Date
August 26, 2022
Empagliflozin
Empagliflozin
Placebo
Placebo
Meitetsu Hospital, Aichi, Nagoya
Chubu Rosai Hospital, Aichi, Nagoya
Daido Hospital, Aichi, Nagoya
Seino Internal Medicine Clinic, Fukushima, Koriyama
Gifu University Hospital, Gifu, Gifu
Watanabe Clinic, Hyogo, Nishinomiya
Institute Medical Corporation Hitomikai Motomachi Takatsuka Naika Clinic, Kanagawa, Yokohama
Medical Corporation KEISEIKAI Kajiyama Clinic, Kyoto, Kyoto
Medical Corporation Hayashi Katagihara Clinic, Kyoto, Kyoto
Iryouhouijneiwakai Minamiakatsuka Clinic, Mito, Ibaraki
Moriya Keiyu Hospital, Moriya, Ibaraki
North Alps Medical Center Azumi Hospital, Nagano, Kitaazumi-gun
Asama Nanroku Komoro Medical Center, Nagano, Komoro
Koshigaya Municipal Hospital, Saitama, Koshigaya
Dojinkinenkai Meiwa Hospital, Tokyo, Chiyoda-ku
Tokyo Asbo Clinic, Tokyo, Chuo-ku
Shinagawa East one Medical Clinic, Tokyo, Minato-ku
Ikebukuro Metropolitan Clinic, Tokyo, Toshima-ku
Lead Sponsor
Boehringer Ingelheim
INDUSTRY